Overview

NCI Definition: A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina. The overall lobular architecture is preserved. It is frequently multifocal (90% in some series) and bilateral. It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma. [1]

Breast lobular carcinoma in situs most frequently harbor alterations in TP53, SYNE1, KAT6A, EXT2, and EP400 [2].

Most Commonly Altered Genes in Breast Lobular Carcinoma In Situ

TP53 c.217-c.1178 Missense, TP53 c.142-c.212 Missense, TP53 c.1-c.137 Missense, TP53 V173M, and TP53 Mutation are the most common alterations in breast lobular carcinoma in situ [2].

Top Alterations in Breast Lobular Carcinoma In Situ

Significant Genes in Breast Lobular Carcinoma In Situ

BRCA1 +

BRCA2 +

ERBB2 +

PTEN +

TP53 +

Disease Details

Synonyms
Lobular carcinoma in situ, Non-Infiltrating Lobular Breast Carcinoma, Lobular Breast Carcinoma In Situ, Lobular Carcinoma In Situ of the Breast (LCIS, Lobular Ca in situ of the Breast, Non-Invasive Lobular Carcinoma of Breast, Non-Infiltrating Lobular Carcinoma, Non-invasive lobular breast carcinoma, Non-infltrating lobular breast carcinoma, lobular carcinoma in situ, Lobular Carcinoma in situ of Breast, Non-Invasive Lobular Breast Carcinoma, Non-Infiltrating Lobular Carcinoma of the Breast, Non-Invasive Lobular Carcinoma of the Breast, LCIS, Lobular Carcinoma In Situ (LCIS), Non-Infiltrating Lobular Carcinoma of Breast, Lobular Carcinoma in situ, Lobular Ca in situ of Breast, Lobular Carcinoma In Situ of the Breast
Parent(s)
Adenocarcinoma In Situ
OncoTree Name
Breast Lobular Carcinoma In Situ
OncoTree Code
LCIS

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.